Increased expression of class III Β-tubulin in castration-resistant human prostate cancer

British Journal of Cancer

Volumn 101, Issue 6, 2009, Pages 951-956

  Terry, S ^a,b,c   Ploussard, G ^a,b   Allory, Y ^a,b,d   Nicolaiew, N ^a,b   Boissiere Michot F ^e   Maille P ^d   Kheuang, L ^a,b   Coppolani, E ^a   Ali, A ^a   Bibeau, F ^e   Culine, S ^a,b,d   Buttyan, R ^f   De La Taille, A ^a,b,d   Vacherot, F ^a,b  

^a INSERM U955   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e Centre Vald Aurelle   (France)

^f ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Class III b tubulin; Disease progression; Hormone therapy; Prostate cancer; Therapeutic resistance

Indexed keywords

ANDROGEN; BETA TUBULIN; BETA TUBULIN CLASS 3; GONADORELIN AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE LEVEL; TUMOR XENOGRAFT;

EID: 70249124131     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605245     Document Type: Article

References (34)

1. Anastasiadis AG, Ghafar MA, Salomon L, Vacherot F, Benedit P, Chen MW, Shabsigh A, Burchardt M, Chopin DK, Shabsigh R, Buttyan R (2002) Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol 128: 358-362
2. Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil Diez de Medina S, Moutereau S, Maille P, Soyeux P, Abbou C, Salomon L, Vacherot F, de La aille A, Loric S, Allory Y (2008) Comparative expression of Hedgehog ligandsat different stages of prostate carcinoma progression. J Pathol 216: 460-470
3. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (2001) Progesterone eceptor expression in human prostate cancer: correlation with tumorprogression. Prostate 48: 285-291
4. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A,Hayek O, Dorai T, Buttyan R (1999) Transdifferentiation of prostate ancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162: 1800-1805
5. Dumontet C, Jordan MA, Lee FF (2009) Ixabepilone: targeting {beta}III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8: 17-25
6. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592 (Pubitemid 46359643)
7. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12: 2774-2779
8. Frigo DE, McDonnell DP (2008) Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 7: 659-669
9. Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C (2008) Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14: 4511-4516
10. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23: 1439-1446 (Pubitemid 46260031)
11. Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67: 9356-9363
12. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565
13. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154-179
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
15. Kamath K, Wilson L, Cabral F, Jordan MA (2005) BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280: 12902-12907
16. Katsetos CD, Herman MM, Mork SJ (2003) Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 55: 77-96
17. Katsetos CD, Kontogeorgos G, Geddes JF, Herman MM, Tsimara-Papastamatiou H, Yu Y, Sakkas LI, Tsokos M, Patchefsky AS, Ehya H, Cooper HS, Provencio J, Spano AJ, Frankfurter A (2000) Differential distribution of the neuron-associated class III beta-tubulin in neuroen-docrine lung tumors. Arch Pathol Lab Med 124: 535-544
18. Kavallaris M, Burkhart CA, Horwitz SB (1999) Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80: 1020-1025
19. Lu Q, Luduena RF (1993) Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18: 173-182
20. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of taxol resistance related to microtubules. Oncogene 22: 7280-7295
21. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91: 11358-11362
22. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
23. Ranganathan S, Salazar H, Benetatos CA, Hudes GR (1997) Immuno-histochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate 30: 263-268
24. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C (2008) Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 30 flanking region. Gene 409: 100-108
25. Rivera E, Lee J, Davies A (2008) Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13: 1207-1223
26. Saussede-Aim J, Matera EL, Ferlini C, Dumontet C (2009) Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton 66: 378-388
27. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA (2008) Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100: 815-825
28. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9: 168-175
29. Shalli K, Brown I, Heys SD, Schofield AC (2005) Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19: 1299-1301
30. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
31. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51
32. Wright ME, Tsai MJ, Aebersold R (2003) Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17: 1726-1737
33. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L, Hatem F, Huang J, Anthony di Sant'Agnese P (2006) Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 30: 705-712
34. Yuan TC, Veeramani S, Lin MF (2007) Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14: 531-547